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Allergic bronchopulmonary aspergillosis mimicking lung cancer in
a non-asthmatic female patient: a case report
Alergiczna aspergiloza oskrzelowo-płucna imitująca guz płuca
u chorej bez astmy oskrzelowej — opis przypadku
Abstract
Allergic bronchopulmonary aspergillosis (ABPA) is a lung disease caused by a hypersensitivity reaction to antigens of the
Aspergillus species (most frequently Aspergillus fumigatus), with a variable radiographic appearance. ABPA most commonly
affects patients with steroid-dependent asthma (1–2%) and patients with cystic fibrosis (5–15%). ABPA is very rarely
diagnosed in non-asthmatics. We report a case of ABPA in a 45-year-old female initially evaluated for suspected cancer of
the left lung with hilar lymphadenopathy, who had never been diagnosed with asthma. After the diagnostic investigation
was complete, the diagnosis of ABPA was established and appropriate treatment was instituted leading to clinical, radiologi-
cal, and serological improvement (IgE decrease).
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Introduction
Allergic bronchopulmonary aspergillosis
(ABPA) is a disorder caused by a hypersensitivity
reaction to antigens of the Aspergillus species (most
frequently Aspergillus fumigatus). ABPA was first
described in 1952 by Hinson et al. [1]. The patho-
genesis of ABPA is complex with immune and ge-
netic factors on the part of the host being implica-
ted. ABPA most commonly affects patients with
allergic diseases, including steroid-dependent asth-
ma (1–2% of ABPA patients) or cystic fibrosis (5–
15% of ABPA patients) [2]. As ABPA is very rarely
diagnosed in patients without a history of asthma,
no data on the incidence of the disease in the ge-
neral population are available [3]. Patients usual-
ly complain of paroxysmal dyspnoea, productive
cough with expectoration of brownish purulent
plugs and-less frequently-general symptoms, such
as fever, weight loss, and asthaenia. ABPA is cha-
racterised by a considerably variable radiographic
appearance with the most common findings being
atelectasis, transient pulmonary infiltrates, proxi-
mal bronchiectasis, and signs of mucoid impaction.
We report a case of a previously healthy fe-
male referred to our Department with suspected
tumour of the left lung.
Case presentation
A 45-year-old female never-smoker with a
long-standing history of allergy, receiving no long-
term medication, an ENT specialist, was admitted
to our Department in December 2009 for diagno-
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leading to the lingula. Microbiological examination
of the bronchial discharge revealed isolated fun-
gal hyphae, and the cultures revealed numerous
Aspergillus fumigatus colonies and isolated Can-
dida albicans colonies. No acid-fast bacilli were
detected. The immediate aspergillin skin test was
positive (5 × 5 mm) and the delayed test was ne-
gative. A positive result was obtained in the sero-
logical test for aspergillosis (IgG) and no IgE anti-
bodies specific for Aspergillus fumigatus were de-
tected. Spirometry did not reveal signs of airway
obstruction, although upon the administration of
a short-acting b2-agonist a marked improvement of
forced expiratory volume in one second (FEV1) was
observed, which was considered a sign of bronchial
hyperreactivity. All these diagnostic investigations
allowed us to rule out lung cancer and confirm the
diagnosis of ABPA (the patient met 6 out of 8 ma-
jor diagnostic criteria proposed by Rosenberg and
Patterson) [4, 5]. The patient was started on gluco-
corticosteroids at the dose of 0.5 mg/kg/day, which
were tapered off after 6 months, and on itracona-
zole at a dose of 200 mg BID for 2 months (due to
the massive fungal growth).
A radiological improvement and a reduction
in serum IgE was observed during the follow-up
after the initiation of treatment.
Discussion
Aspergillus is a common mould which acco-
unts for 0.1–22% of all fungal spores in air sam-
ples. Although about 250 species of this fungus
have been described so far, only some of them are
stic evaluation of a left lung tumour. Since July
2009 she had been complaining of a cough with
expectoration of mucopurulent sputum without
haemoptysis, dyspnoea, or fever. Despite several
courses of antibiotics (clarithromycin, cefuroxime,
metronidazole) the cough kept returning after pe-
riods of temporary improvement. In November
2009 a chest X-ray revealed partial atelectasis of
the upper lobe of the left lung with sparing of the
lingula, suggestive of a lung tumour (Figure 1). The
chest CT scan performed at that time confirmed
atelectasis of the upper lobe of the left lung. The
patient underwent diagnostic evaluation for can-
cer at an outpatient oncology facility, where she
underwent flexible bronchoscopy revealing infil-
tration of the bronchus and the carina leading to
segment 1–2 of the left lung, pus filling the bron-
chus, and infiltration of the bronchus leading to
the lingula. Histopathological examination of the
tissue samples collected from the left upper lobe
bronchus revealed massive inflammatory changes
with necrotic masses with signs of low-degree dys-
plasia focally in the metaplastic epithelium. Ne-
ither cytological examination of the bronchial wa-
shings nor bronchial brushing revealed tumour
cells. Microbiological examination of the bronchial
washings revealed a confluent growth of Aspergil-
lus fumigatus and the presence of numerous Char-
cot-Leyden crystals. The patient was then admit-
ted to the Institute of Tuberculosis and Lung Dise-
ases in Warsaw for continuation of the diagnostic
evaluation.
On admission the patient was in a good gene-
ral condition without cough, any other respirato-
ry symptoms, or fever. She said she had lost about
5 kg in the past month. Chest auscultation reve-
aled crepitations over the anterior chest wall in the
midclavicular line and anterior axillary line on the
left. Differential blood cell count revealed an eosi-
nophilia of 1.6 × 199/l (16.4%) and a marked ele-
vation of immunoglobulin E (IgE) to 1400 IU/ml.
A chest X-ray revealed a widened outline of the left
hilum with atelectasis of the lingula (Figure 2). A
chest CT scan revealed proximal bronchiectasis in
segment 3 of the upper lobe of the left lung and
the lingula with retention of discharge, causing
partial atelectasis of the lingula and fine intralo-
bular nodules consistent with retained discharge
in the small airways with reactively enlarged
lymph nodes in the mediastinum (Figure 3). Com-
pared to the previous radiograms, based on the
variable presentation of the pulmonary changes, a
suspicion of ABPA was raised. Flexible broncho-
scopy revealed severe inflammatory changes with
purulent discharge and plugging of the bronchus
Figure 1. Postero-anterior X-ray of the chest — left upper lobe
atelectasis sparing lingula
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human pathogens, e.g. Aspergillus fumigatus (90%),
Aspergillus flavus, Aspergillus niger. They do not
cause disease in all the people. Depending on the
individual’s immune status, the diseases caused by
Aspergillus may be saprophytic (aspergilloma), al-
lergic (ABPA, allergic aspergillosis of the parana-
sal sinuses, allergic alveolitis) or invasive (invasi-
ve aspergillosis) [6].
ABPA is a disease caused by hypersensitivity
to antigens of moulds, most commonly to antigens
of Aspergillus fumigatus, which usually develops
in patients suffering from asthma or cystic fibro-
sis, usually in the presence of atopy. The increased
viscosity of the mucus in the respiratory tract in
some of the patients with asthma and cystic fibro-
sis combined with impaired mucociliary clearan-
ce in cystic fibrosis disrupts the process of effecti-
ve removal of the fungal spores from the bronchi.
The susceptibility to the development of ABPA is
also a result of genetic factors that determine in-
flammatory response in atopic patients, which
determines activation of T and B cells specific for
Aspergillus [7, 8]. Five stages of the disease, which
may develop in various orders, are distinguished:
stage I (acute), stage II (remission), stage III (exa-
cerbation), stage IV (steroid dependent), and stage
V (fibrotic). The disease may be insidious with
periods of exacerbation and periods of remission,
and early diagnosis may prevent the progression
of the disease, damage to the pulmonary intersti-
tium, and pulmonary function deterioration [7].
The major diagnostic criteria of ABPA inclu-
de [4, 7, 8]: (1) asthma, (2) pulmonary infiltrates
on radiograms, (3) positive immediate aspergillin
skin test (type I hypersensitivity), (4) peripheral
blood eosinophilia (> 1000/mm3), (5) serum pre-
cipitins (IgG) to Aspergillus fumigatus, (6) total se-
rum IgE exceeding 427 IU/ml (1000 ng/ml) [9, 10],
(7) central bronchiectasis, and (8) serum IgE and/
or IgG specific for Aspergillus. The minor diagno-
stic criteria of ABPA include the presence of Asper-
gillus in the sputum, expectoration of brownish
plugs and a positive delayed aspergillin skin test
(type III hypersensitivity). The diagnosis of ABPA
may be confirmed if at least 6 major criteria are
met, although it is also acceptable to confirm the
diagnosis based on the minimum criteria (without
the presence of peripheral blood eosinophilia and
antibodies specific for Aspergillus fumigatus).
ABPA is also divided into seropositive ABPA,
ABPA without central bronchiectasis, and ABPA
with central bronchiectasis [2, 4, 6]. The disease
usually affects patients with asthma or cystic fi-
brosis. In our case the patient had never been dia-
gnosed with asthma but she had allergies to inha-
lation allergens and fulfilled 6 out of the 8 diagno-
stic criteria of ABPA.
In 1981, Glancy et al. described a group of 11
patients with ABPA without a previous diagnosis
of asthma but half of whom were atopic (allergic
rhinitis, hay fever). During the follow-up some of
them developed asthma 2–10 years later [3]. In
1982, Berkin et al. described a group of 5 patients
with ABPA without asthma, with only 1 patient
presenting manifestations of hay fever [11]. Aller-
gic aspergillosis has also been reported in isolated
Figure 2. Postero-anterior X-ray of the chest — partial regression
of the upper lobe lesions, atelectasis of lingula appeared
Figure 3. High resolution computed tomography of the lung —
bronchiectasis within atelectatic lingula
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cases of hyper IgE syndrome, bronchocentric gra-
nulomatosis and chronic granulomatous disease,
bronchiectasis secondary to past tuberculosis, Kar-
tagener’s syndrome, and chronic obstructive pul-
monary disease [2, 6]. Until 2009 a total of 36 ca-
ses of ABPA without asthma had been described.
It is believed that due to the low frequency of this
phenomenon these patients are usually evaluated
for lung cancer or diagnosed with pulmonary tu-
berculosis, so the actual number of patients with
ABPA is in fact underestimated [6].
A characteristic feature of ABPA is the varia-
ble radiographic appearance. The most common X-
ray features include transient pulmonary infiltra-
tes (mainly in the upper and lower lobes), atelec-
tasis, band-like opacities (the gloved finger sign),
bronchiectasis and — less frequently — areas of
poor vascular pattern, cavities, and signs of fibro-
sis. The most common findings on chest CT inclu-
de: bronchiectasis with a predominance of proxi-
mal changes, signs of atelectasis, mucoid impac-
tion, local areas of consolidation and — less fre-
quently — changes of an air trap nature, cavities,
fibrosis, and pleural thickening [2]. Our patient
was initially evaluated for suspected cancer of the
left lung with hilar lymphadenopathy. Although
such a manifestation of allergic aspergillosis is rare,
several cases of ABPA have been reported in En-
glish-language journals. In 1982, Berkin et al. de-
scribed 4 patients with complete or partial atelec-
tasis without a history of asthma in whom the fi-
nal diagnosis was ABPA [11]. In 2001, Sanchez-
Alcaros et al. described a 65-year-old male smo-
ker without a history of asthma who had undergo-
ne thoracotomy due to suspected lung cancer,
which revealed the presence of dilated bronchi fil-
led with mucus. The patient was eventually dia-
gnosed with ABPA a year later [12]. In 1998, Cote
et al. described a case of a 51-year-old female with
mild asthma who was being evaluated due to ha-
emoptysis and a peripheral tumour of the right
lung. This patient was also eventually diagnosed
with ABPA [13]. In 2006, Agarwal et al. described a
case of a 60-year-old female evaluated due to the
widening of the left hilum on a chest X-ray. A high
resolution computed tomography (HRCT) scan re-
vealed proximal bronchiectasis and numerous bron-
chocele, which mimicked hilar lymphadenopathy
on a chest X-ray, as was the case with our patient.
After additional investigations had been carried out,
the diagnosis of ABPA was confirmed [14].
In the case of our patient, the first flexible
bronchoscopy performed in an outpatient setting
revealed infiltration of the bronchus and the cari-
na leading to segment 1–2 and the bronchus le-
ading to the lingula and the presence of pus filling
the bronchi, and the histopathological examination
of the sections of the bronchial mucosa revealed
epithelial metaplasia with signs of low-degree dys-
plasia, which worried the doctors performing the
examination. Usually, flexible bronchoscopy in
patients with ABPA reveals severe inflammation
with a thickened mucosa, bronchiectasis, ample
amounts of purulent discharge, and the presence
of pus plugs blocking the bronchi. Glucocortico-
steroids, usually given at a dose of 0.5 mg/kg/day,
are the treatment of choice in ABPA. They suppress
the immune response to the fungus and exert an
anti-inflammatory action. There is no consensus
as to the duration of glucocorticosteroid treatment.
It is, however, known that the use of lower doses
is associated with more rapid relapses and the de-
velopment of steroid dependence. Treatment is
usually given for 6 months, although extending the
duration of treatment to 12 months and increasing
the dose (to 0.75 mg/kg/day) is associated with a
higher rate of remissions and a lower rate of stero-
id dependence. After 6–8 weeks of treatment a de-
crease in IgE and a radiological improvement sho-
uld be seen. The treatment goal is to reduce the
baseline IgE levels by 35–50%, although it should
be remembered that after treatment IgE levels need
not be normal. In each patient the baseline serum
IgE level should be determined, as a 100% incre-
ase suggests a risk of relapse. Each patient in the
initial phase of treatment should be monitored
every 6–8 weeks for the first year, followed by every
6–12 months [2, 6]. Our patient, due to the nature
of her work, did not return for follow-up asses-
sments, although about 8 months after treatment
completion her IgE levels were found to have de-
creased by 50%, but the infiltrates in the right lung
are still present and require follow-up. Publications
on the management of ABPA do not unequivocally
report on the justifiability of antifungal treatment.
It is believed that antifungal treatment may suppress
the growth of fungi colonising the patient’s airways
and at the same time reduce the exposure to Asper-
gillus antigens. It is believed that the addition of itra-
conazole to glucocorticosteroids at a dose of 200 mg
BID for 16 weeks, followed by 200 mg QD for the
next 16 weeks allows, in nearly half of the patients,
a reduction of the dose of glucocorticosteroids, im-
proves exercise tolerance, decreases total IgE, and
improves FEV1 [9, 15]. However, due to the insuffi-
cient number of studies, it is not recommended to
combine glucocorticosteroids with antifungals as a
standard course of action in the basic treatment of
ABPA; this option is reserved for patients with re-
current disease.  Despite the fact that the patient was
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started on two-month antifungal treatment due to
the confluent growth of fungi in bronchial washing
cultures and considerable exposure at the workpla-
ce, the treatment resulted in elimination of the fun-
gus from the bronchi.
In conclusion, it should be emphasised that
ABPA is a frequently underdiagnosed condition
associated exclusively with the presence of asth-
ma or cystic fibrosis. It may, however, also deve-
lop in patients without atopy and may sometimes
suggest other, much more common disease enti-
ties including tuberculosis and lung tumours,
which should always be included in the differen-
tial diagnosis. Also, not all the diagnostic criteria
are always fulfilled, which makes establishment of
the final diagnosis difficult. However, the disease
should be detected as soon as possible because
prompt initiation of treatment may prevent irrever-
sible pulmonary fibrosis and disability.
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